United Therapeutics Corporation (UTHR)
| Market Cap | 25.18B +27.3% |
| Revenue (ttm) | 3.19B +1.9% |
| Net Income | 1.23B -3.2% |
| EPS | 26.53 +0.6% |
| Shares Out | 42.59M |
| PE Ratio | 22.28 |
| Forward PE | 23.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 446,806 |
| Open | 593.31 |
| Previous Close | 593.31 |
| Day's Range | 587.00 - 598.84 |
| 52-Week Range | 455.63 - 614.23 |
| Beta | 0.48 |
| Analysts | Buy |
| Price Target | 687.14 (+16.23%) |
| Earnings Date | Nov 4, 2026 |
About UTHR
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre... [Read more]
Financial Performance
In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price target is $687.14, which is an increase of 16.23% from the latest price.
News
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will prov...
United Therapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of United Therapeutics (UTHR) with a Buy rating and $660 price target The firm says the company has evoled into a multi-route pulmonary hypertension platform. Publishe...
United Therapeutics price target raised to $568 from $566 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on United Therapeutics (UTHR) to $568 from $566 and keeps an Equal Weight rating on the shares. The company posted…
United Therapeutics price target raised to $725 from $697 at RBC Capital
RBC Capital raised the firm’s price target on United Therapeutics (UTHR) to $725 from $697 and keeps an Outperform rating on the shares. Q3 was a net positive for United…
United Therapeutics price target raised to $700 from $675 at TD Cowen
TD Cowen analyst Joseph Thome raised the firm’s price target on United Therapeutics (UTHR) to $700 from $675 and keeps a Buy rating on the shares. The firm said Tyvaso…
United Therapeutics price target raised to $703 from $700 at Wells Fargo
Wells Fargo raised the firm’s price target on United Therapeutics (UTHR) to $703 from $700 and keeps an Overweight rating on the shares. The Tyvaso beat is a clear positive,…
United Therapeutics Earnings Call Transcript: Q3 2026
Q3 revenue and Tyvaso revenue reached records as demand and commercial execution strengthened. The pipeline strategy is broadening, while the soft-mist NDA shifted to 2027 and ralinepag faces API-supplier remediation risks.
United Therapeutics Quarterly report: Q3 2026
United Therapeutics has published its Q3 2026 quarterly earnings report on November 4, 2026.
United Therapeutics Earnings release: Q3 2026
United Therapeutics released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
United Therapeutics Slides: Q3 2026
United Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
United Therapeutics announces buydown of Ralinepag royalty
United Therapeutics (UTHR) announced that it has entered into an amendment with Arena Pharmaceuticals, a subsidiary of Pfizer (PFE), which eliminates all royalty obligations under its exclusive licens...
United Therapeutics Announces Buydown of Ralinepag Royalty
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that it has entered into an amendment w...
United Therapeutics reports Q3 EPS $5.71, consensus $6.04
Reports Q3 revenue $832.5M, consensus $781.14M. “United Therapeutics (UTHR) is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increa...
United Therapeutics reports Q3 EPS $5.71, consensus $6.04
Reports Q3 revenue $832.5M, consensus $781.14M. “United Therapeutics (UTHR) is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increa...
United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...
United Therapeutics price target lowered to $695 from $710 at JPMorgan
JPMorgan lowered the firm’s price target on United Therapeutics (UTHR) to $695 from $710 and keeps an Overweight rating on the shares.
United Therapeutics Rising Ahead of Next Earnings Report
Shares of United Therapeutics Corporation (UTHR) gain 4,517% since Big Money bought big in 2004.
United granted FDA clearance to proceed with trial of Treprostinil-Iloprost SMI
United Therapeutics (UTHR) announced that the U.S. Food and Drug Administration, FDA, has granted clearance under the company’s Investigational New Drug application to proceed with a clinical trial of...
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administra...
United Therapeutics price target raised to $850 from $700 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on United Therapeutics (UTHR) to $850 from $700 and keeps an Overweight rating on the shares. United Therapeutics retains upside potential despite limi...
United Therapeutics price target raised to $850 from $700 at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders raised the firm’s price target on United Therapeutics (UTHR) to $850 from $700 and keeps an Overweight rating on the shares. Published first on…
United Therapeutics price target lowered to $697 from $708 at RBC Capital
RBC Capital lowered the firm’s price target on United Therapeutics (UTHR) to $697 from $708 and keeps an Outperform rating on the shares. The top questions from investors have been…
United Therapeutics announces new share repurchase program for up to $2B
United Therapeutics (UTHR) announced that the company’s Board of Directors has authorized a new share repurchase program for up to $2 billion of the company’s common stock, available through October…
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors...
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a pre...